GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Beneish M-Score

Macrogenics (Macrogenics) Beneish M-Score : -4.99 (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.99 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Macrogenics's Beneish M-Score or its related term are showing as below:

MGNX' s Beneish M-Score Range Over the Past 10 Years
Min: -4.99   Med: -2.01   Max: 1.94
Current: -4.99

During the past 13 years, the highest Beneish M-Score of Macrogenics was 1.94. The lowest was -4.99. And the median was -2.01.


Macrogenics Beneish M-Score Historical Data

The historical data trend for Macrogenics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Beneish M-Score Chart

Macrogenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.49 -2.04 -4.51 -0.42 -4.99

Macrogenics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -2.05 -3.78 -3.13 -4.99

Competitive Comparison of Macrogenics's Beneish M-Score

For the Biotechnology subindustry, Macrogenics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Macrogenics's Beneish M-Score falls into.



Macrogenics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Macrogenics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4847+0.528 * 1.1112+0.404 * 0.9452+0.892 * 0.3804+0.115 * 0.9898
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.3271+4.679 * -0.274055-0.327 * 1.0304
=-4.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $10.37 Mil.
Revenue was 9.164 + 10.397 + 13.136 + 24.213 = $56.91 Mil.
Gross Profit was 9.001 + 7.038 + 11.959 + 20.69 = $48.69 Mil.
Total Current Assets was $251.34 Mil.
Total Assets was $298.42 Mil.
Property, Plant and Equipment(Net PPE) was $45.69 Mil.
Depreciation, Depletion and Amortization(DDA) was $9.65 Mil.
Selling, General, & Admin. Expense(SGA) was $52.19 Mil.
Total Current Liabilities was $56.11 Mil.
Long-Term Debt & Capital Lease Obligation was $30.20 Mil.
Net Income was -46.072 + 17.554 + 57.469 + -38.009 = $-9.06 Mil.
Non Operating Income was 0 + 50 + 100.93 + 0 = $150.93 Mil.
Cash Flow from Operations was -28.037 + -35.246 + -2.089 + -12.833 = $-78.21 Mil.
Total Receivables was $56.22 Mil.
Revenue was 71.176 + 41.734 + 26.007 + 10.673 = $149.59 Mil.
Gross Profit was 69.385 + 38.591 + 23.605 + 10.625 = $142.21 Mil.
Total Current Assets was $222.18 Mil.
Total Assets was $280.47 Mil.
Property, Plant and Equipment(Net PPE) was $56.91 Mil.
Depreciation, Depletion and Amortization(DDA) was $11.87 Mil.
Selling, General, & Admin. Expense(SGA) was $58.95 Mil.
Total Current Liabilities was $48.61 Mil.
Long-Term Debt & Capital Lease Obligation was $30.11 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(10.367 / 56.91) / (56.222 / 149.59)
=0.182165 / 0.375841
=0.4847

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(142.206 / 149.59) / (48.688 / 56.91)
=0.950638 / 0.855526
=1.1112

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (251.339 + 45.693) / 298.418) / (1 - (222.18 + 56.91) / 280.468)
=0.004644 / 0.004913
=0.9452

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=56.91 / 149.59
=0.3804

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(11.865 / (11.865 + 56.91)) / (9.645 / (9.645 + 45.693))
=0.172519 / 0.174293
=0.9898

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(52.188 / 56.91) / (58.949 / 149.59)
=0.917027 / 0.39407
=2.3271

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((30.196 + 56.108) / 298.418) / ((30.106 + 48.611) / 280.468)
=0.289205 / 0.280663
=1.0304

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-9.058 - 150.93 - -78.205) / 298.418
=-0.274055

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Macrogenics has a M-score of -4.99 suggests that the company is unlikely to be a manipulator.


Macrogenics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Macrogenics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics (Macrogenics) Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Executives
Ezio Bonvini officer: Sr VP, Research & CSO 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz director
Jeffrey Stuart Peters officer: Acting General Counsel 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu director C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels officer: SVP, CFO and Secretary 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel officer: Sr VP, BPD & Manufacturing 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser officer: Sr VP & Chief Business Officer 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith director OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck officer: Chief Medical Officer 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949